InsidersTradesSigma
Track the Syngene Intl stock price and the full directors' dealings record of the company, a publicly traded company based in India. Shares are listed on IN IN, under the authority of SEBI (PIT + SAST). Market capitalisation: €175.7bn. The latest transaction was disclosed on 26 May 2026 (Acquisition). Among the most active insiders: Nippon India Mutual Fund. The full history is accessible without an account.
Analysts rate Syngene Intl Buy (bullish), based on 8 analysts. Average price target: ₹562.50.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Syngene Intl is a biotechnology company based in India, specializing in research and development solutions for the pharmaceutical and biopharmaceutical industries.